Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $445.0 million.

  • Indivior Pharmaceuticals' Cash & Equivalents rose 4082.28% to $445.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.0 million, marking a year-over-year increase of 4082.28%. This contributed to the annual value of $319.0 million for FY2024, which is 94.94% up from last year.
  • Indivior Pharmaceuticals' Cash & Equivalents amounted to $445.0 million in Q3 2025, which was up 4082.28% from $510.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Cash & Equivalents registered a high of $1.1 billion during Q4 2021, and its lowest value of $302.0 million during Q2 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $510.0 million (2025), whereas its average is $596.8 million.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Cash & Equivalents tumbled by 5917.31% in 2023, and later soared by 6887.42% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Cash & Equivalents stood at $1.1 billion in 2021, then fell by 29.76% to $774.0 million in 2022, then tumbled by 59.17% to $316.0 million in 2023, then grew by 0.95% to $319.0 million in 2024, then surged by 39.5% to $445.0 million in 2025.
  • Its last three reported values are $445.0 million in Q3 2025, $510.0 million for Q2 2025, and $372.0 million during Q1 2025.